Key facts
- HistoSonics’s last known valuation is $610.0M (Aug 2024).
- It has raised $250.0M across 3 recorded rounds; the latest was Later Stage VC ($102.0M) in Jul 2024.
- Notable investors include Founders Fund, K5 Global, Alpha Wave Global, Wellington Management, Johnson & Johnson JJDC — 16 tracked in total.
- HistoSonics has filed 4 Form Ds with the SEC since 2020, most recently Aug 2024 ($102.0M sold to 39 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for HistoSonics
Funding rounds
3 roundsAbout HistoSonics
Developer of a non-invasive and robotically assisted ultrasound therapy device designed for precise tissue destruction. The company's device utilizes focused sound energy to mechanically break down targeted tissue at a sub-cellular level, offering continuous visualization, real-time physician control, and personalized treatment adjustments. operates without incisions or needles, integrating advanced imaging and adaptive energy delivery, enabling healthcare providers to treat unresectable tumors with enhanced accuracy, reduced procedural complexity, and minimized patient recovery time.
- Sector
- Healthcare
- HQ
- Plymouth, MN, United States
- Founded
- 2009
- Employees
- 283
- Website
- histosonics.com/
- Ownership
- Privately Held (backing)
HistoSonics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in HistoSonics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on HistoSonics in its N-PORT filings yet. We sweep new filings monthly.